Morningstar - Trustpower (TPW) Strong First Half for Trustpower; No change to FVE

Report

Morningstar

Adrian Atkins

EUR 101.80 For Business Accounts Only

Strong First Half for Trustpower; No change to FVE

Trustpower posted a strong first-half fiscal 2018 result, with EBITDA up 44% to NZD 159 million and adjusted net income increasing 82% to NZD 83 million. The good result was underpinned by a strong generation performance on favourable rainfall, as well as a pleasing improvement in telecom profitability and good operating cost control. We increase our fiscal 2018 EBITDA forecast marginally to NZD 268 million, at the top of the recently upgraded guidance range of between NZD 255 and 270 million. W...

06/11/2017 13 EN

Underlying

Trustpower

Trustpower is an electric power generation and retail group based in New Zealand. Co. and its subsidiaries are engaged in the development, ownership and operation of electricity generation facilities from renewable energy sources and the retail sale of electricity and telecommunications services to its customers. Co. owns and maintains 36 small to medium size Hydro Generating Stations and two Wind Farms, with a further Wind Farm in South Australia. Co. is engaged in the production of electricity from renewable sources and its power stations produce enough electricity for around 220,000 New Zealand households.

See profile

NZTPXE0001S5 NZX New Zealand

Provider

Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

See profile

Analysts

Adrian Atkins

Other Reports on these Companies

Morningstar

Morningstar | Trustpower Reports In Line FY19 Result; FVE Up 3%

Narrow-moat Trustpower finished the 2019 fiscal year broadly in line with expectations. Underlying net profit after tax, or NPAT, was down 24% from the previous corresponding period, or pcp, to NZD 103 million; while EBITDA fell 9% to NZD 222 million. Both were 1% below our forecasts. Positively, the retail division continues to grow, with adjusted EBITDA up 3% mainly on higher electricity margins. However, generation volumes fell from stellar fiscal 2018 levels because of lower rainfall, causing generation EBITDA to fall 13%. Management guided to fiscal 2020 EBITDA of NZD 205-225 million. Th...

EUR 850.00

May 14, 2019 May 14, 2019 3 EN

Morningstar

Morningstar | Trustpower Offers a Solid Dividend Yield, But Don't Expect Much Earnings Growth

Trustpower generates and supplies electricity to residential, commercial, and industrial consumers. It is considered to have a narrow economic moat, underpinned by its low-cost hydroelectric assets and the efficiently scaled electricity market. The electricity market in New Zealand can be volatile, driven by hydrology conditions, retail competition, and surplus capacity. Trustpower has done a credible job of managing this volatility by hedging its electricity exposure and gradually lifting its own generation capacity. This, coupled with high service levels, good project execution, and innovati...

EUR 850.00

May 14, 2019 May 14, 2019 3 EN

Morningstar

Trustpower Reports In Line FY19 Result; FVE Up 3%

EUR 100.00

May 14, 2019 May 14, 2019 13 EN

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Contract manufacturer Lonza reported solid half-year results, with over CHF 2.9 billion in total sales year to date, up about 6.4% from last year and boosted by foreign exchange tailwinds. Core EBITDA margin expanded 30 basis points from last year to about 27.8%, helped slightly by new accounting standards. Management indicated that it continues to expect mid- to high-single-digit sales growth in 2019. We are maintaining our fair value estimate of CHF 210 per share and our no-moat rating. The ph...

EUR 100.00

July 25, 2019 July 25, 2019 13 EN

Damien Conover

Damien Conover

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

We don't expect any major changes to our AstraZeneca fair value estimate following second-quarter results that largely fell in line with our expectations and slightly ahead of consensus expectations. Overall, the company is posting leading Big Pharma sales growth with total sales up 18% operationally year over year, led by impressive cancer drug sales growth of 57%. Astra's ability to continue to bring next generation drugs to the market that address unmet medical need (especially in oncology) s...

EUR 100.00

July 25, 2019 July 25, 2019 14 EN

Damien Conover

Damien Conover

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

EUR 100.00

July 25, 2019 July 25, 2019 14 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Strong First Half for Trustpower; No change to FVE

Morningstar | Trustpower Reports In Line FY19 Result; FVE Up 3%

Morningstar | Trustpower Offers a Solid Dividend Yield, But Don't Expect Much Earnings Growth

Trustpower Reports In Line FY19 Result; FVE Up 3%

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe